MedPath

The Transcriptomic Study of Thai Patients With Atopic Dermatitis by Tape Strips

Not Applicable
Not yet recruiting
Conditions
Atopic Dermatitis
Interventions
Genetic: Tape strips
Registration Number
NCT05598762
Lead Sponsor
Queen Sirikit National Institute of Child Health
Brief Summary

This study will be use the tape strip technique to evaluate the skin biomarkers of atopic dermatitis among Thai patients to differentiate clinical phenotype.

Detailed Description

The patients will be enrolled in this study if they have been diagnosed with atopic dermatitis. All participants (AD patients and controls) will be evaluated their skin biomarkers by using tape stripping. The tape strips will be applied to the antecubital fossa to collect the epithelial samples. Then RNA was extracted from the tape strips for mRNA profiling to identify the immune and epidermal barrier genes.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Children (age 1-18 years old) with mild atopic dermatitis
  • Children (age 1-18 years old) with moderate to severe atopic dermatitis
  • Children (age 1-18 years old) with moderate to severe atopic dermatitis and food allergy
  • Adult (age 18-60 years old) with atopic dermatitis
  • Healthy individuals (1-60 years old)
  • Patients with asthma (1-60 years old)
Exclusion Criteria
  • Active skin infections
  • Used systemic immunosuppressants within 4 weeks
  • Used topical steroids or immunomodulators within 1 week
  • Used moisturizers within 12 hours before evaluation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Children with food allergy and moderate-severe atopic dermatitisTape strips* age 1-8 years old * moderate or severe degree of atopic dermatitis * IgE mediated food allergy
Children with mild atopic dermatitisTape strips* age 1-8 years old * mild degree of atopic dermatitis
Healthy with AsthmaTape strips* age 1-8 years old * doctor diagnosed asthma * no history of chronic or chronic relapsing eczema
Adult with atopic dermatitisTape strips* age 18-60 years old * mild-severe atopic dermatitis
Children with moderate-severe atopic dermatitisTape strips* age 1-8 years old * moderate or severe degree of atopic dermatitis
HealthyTape strips* age 1-60 years old * no history of atopic diseases
Primary Outcome Measures
NameTimeMethod
Immune biomarkers1 month

Evaluated by RNA sequencing: RNA was extracted for real-time polymerase chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0

Cellular AD biomarkers1 month

Evaluated by RNA sequencing: RNA was extracted for real-time polymerase chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0

Barrier biomarkers1 month

chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Queen Sirikit National Institute of Child Health

🇹🇭

Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath